Open AccessRituximab for the treatment of Churg-Strauss syndrome with renal involvement
Author(s) -
Rodrigo CartinCeba,
Karina A. Keogh,
Ulrich Specks,
S. Sethi,
Fernando C. Fervenza
Publication year - 2011
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfq852
Subject(s) - medicine , rituximab , anti neutrophil cytoplasmic antibody , renal biopsy , vasculitis , gastroenterology , glucocorticoid , kidney disease , immunology , kidney , disease , lymphoma
Churg-Strauss syndrome (CSS) is a small vessel systemic vasculitis associated with asthma and eosinophilia that causes glomerulonephritis (GN) in ∼25% of patients. Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody that depletes B cells and is effective in numerous autoimmune diseases including antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. We aim to evaluate the safety and efficacy of RTX in inducing remission of renal disease activity in patients with CSS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom